Next Sequence

Navigare Ventures is an early-stage investor specialized in science-driven companies. Through our investments, we strengthen the industrial and societal impact of research, as well as the long-term financial capacity of our owners, Wallenberg Investments AB. Our core investment themes within deep tech are underpinned by our knowledge and network in a number of scientific fields and industries. These include advanced computing and quantum technologies, synthetic biology and bio innovation, advanced materials and nano technology as well as data-driven life science. We are long term investors - Seed and Series A and beyond - and form deep and lasting partnerships with founders and entrepreneurs. Our extensive industrial and scientific networks gives us the opportunity to provide capital, network, and know-how to transform promising science start-ups into successful companies. Who we are Navigare Ventures, based in Stockholm, is a fully owned subsidiary of Wallenberg Investments AB. We are a team of scientists, industrialists and entrepreneurs who understand the challenges of turning cutting-edge technologies to successful ventures. As part of the Wallenberg ecosystem, our returns fuel the next generation of scientific advancement through research funding from the Wallenberg Foundations to Swedish universities. What we are looking for We partner with experienced entrepreneurial teams that combine scientific excellence with strong business acumen. In this respect, your company should have a unique offering based on a profound understanding of your scientific or technological field and its market and industrial environment. You should also be capable of demonstrating the viability and commercial potential of your product by engaging with real customers. You are raising capital to scale the R&D, production, marketing, and sales capabilities of your company. Our investment philosophy We only invest in companies we understand. While this is an important general principle in any investment activity, it is even more important when making early-stage investments in new technology. If we don’t understand your science, we won’t understand what experts tell us about the value chain and how it works, or what the competitive landscape looks like. And most importantly, we won’t be able to help you develop your strategy and navigate through the challenges of deep-tech start-ups. So, when preparing a meeting with us, don’t put too much emphasis on future revenue projections. That’s important too, in due time. But first, be prepared for long sessions in front of a whiteboard, explaining to us how your material, algorithm, or antibody functions. We don’t need to understand all the equations, but we need to get the heuristics. We are scientists at heart, eager to learn, and we carry a deep conviction that the world is fundamentally understandable. Core investment themesAdvanced computing and quantum technologies: Digitization and automation deepens in industry and society, driven by breakthroughs in computing and AI. Our focus includes improving existing technologies as well as finding completely new platforms in AI and other areas of applied mathematics as well as in novel computer architectures, communication technology, hardware and design. Synthetic biology and bio innovation: Synthetic biology and bio innovations contribute to a more sustainable society. Companies in this field often combine principles of biology, engineering, and computer science for the development of new biological products and manufacturing methods. Advanced materials and nano technology: New materials and nanoscale technology enable disruptions with the potential to benefit numerous existing industries. From quantum materials to biomaterials and biologically inspired nanostructures, we look for the most promising technology platforms in the field. Data-driven life science: Combining digital technology and data with life science drives scientific understanding and enables novel products. Our focus is on data-driven methods to increase personalization and precision of medical interventions, accelerate product development, digitalize care among other advancements.

Vsquared Ventures backs entrepreneurs engineering the seemingly impossible. We are early-stage investors in deep-tech companies tackling society's most pressing challenges, with an emphasis on quantum and novel computing, green energy, robotics, Al/ML, new space, synthetic biology, and healthcare. Our team of founders, academics, operators and innovators has invested in over 30 companies to date and built one of Europe's strongest deep-tech portfolios, forging alliances with key players in industry, research, and a global startup ecosystem along the way. The companies we've partnered with so far include Isar Aerospace, IOM, Zama, The Exploration Company, and Custom Cells.

CDL has designed a new approach to enterprising research and innovation, nurturing an entrepreneurial mindset through expert opinion, funding opportunities, research analysis, and business development support. CDL’s objective-setting process enhances the performance of technical founders who learn from the insights of experienced entrepreneurs, increasing their probability of success. The Program involves:Mentorship from select entrepreneurs and angel investors: the Fellows and Associates Intensive full-day sessions with the CDL Mentors take place every eight weeks with the purpose of assessing progress and setting new short-term objectives. Fellows and Associates provide professional judgment (entrepreneurial knowledge) to help guide CDL Ventures and prioritize actions. The program is designed for early-stage, science-based technology companies, though we consider all applicants based on their potential to scale and the viability of their product. CDL’s objective-setting process enhances the performance of technical founders who learn from the insights of experienced entrepreneurs, increasing their probability of success. Opportunities to raise capital CDL Mentors are made up of a carefully selected group of exited entrepreneurs, angel investors, and partners from leading venture capital firms. These participants often invest in ventures that demonstrate a track record of achieving their objectives. Advice on technology roadmaps from CDL’s Chief Scientists World-renowned experts from leading academic institutions provide technical feedback to founders and advise the Fellows and Associates on objectives related to technology validation. Business development support from top students Business school students work to support ventures including developing financial models, evaluating potential markets, and fine-tuning strategies for scaling. Twelve locations globally CDL operates five sites in Canada, three in the United States and four in Europe. Launched in 2012 at the Rotman School of Management at University of Toronto, the program has now expanded with locations in Oxford (Saïd Business School, University of Oxford), Paris (HEC Paris), Atlanta (Scheller College of Business, Georgia Institute of Technology), Madison (Wisconsin School of Business, University of Wisconsin-Madison), Seattle (University of Washington, Foster School of Business), Berlin (European School of Management and Technology), Tartu (Delta Management School, University of Tartu), Vancouver (Sauder School of Business, University of British Columbia), Montreal (HEC Montréal), Calgary (Haskayne School of Business, University of Calgary), and Halifax (Rowe School of Business, Dalhousie University).

Lingotto’s Innovation Fund is a new $600mm+ AUM crossover (public & private) fund focused on making concentrated and long-term investments in companies operating at the cutting edge of technological and business-model innovation. Core to our investment thesis is the fact that market returns are dominated by extreme structural winners – we seek to identify decades-long secular trends and the management teams best positioned to capitalize on them in the early years. The senior team has a notable history of private investments including: OpenAI, SpaceX, Alibaba, Coupang, Stripe, Databricks, Spotify, Airbnb, Tempus, Recursion, Ginkgo Bioworks, Palantir, Epic Games, Joby Aviation, Indigo, Aira, Humane, H2 Green Steel. The Innovation Fund is co-managed by James Anderson (CIO & Managing Partner) and Morgan Samet (Co-Head & Managing Partner). James has over 40 years of investment experience – most recently as a Partner at Baillie Gifford, where he managed over £100bn in AUM throughout his tenure. As head of the firm’s flagship fund, the Scottish Mortgage Investment Trust, he delivered a +1,555% return vs. +354% for the FTSE all-world benchmark (between April 2000 and March 2022). He was instrumental in the firm’s move into private investing starting with Alibaba in 2012. Morgan has over 19 years of experience in private and public market investing. She has previously worked at Belfer Management, Pzena Investment Management, Thomas H. Lee Partners, and Goldman Sachs. She received her MBA from Harvard Business School. The Innovation Fund is a part of Lingotto, a $4.5bn+ investment management company supported with permanent capital from Exor and additional external LPs. Exor is one of Europe’s largest publicly traded holding companies. Its assets include companies like Stellantis (Fiat, Chrysler, Citroen), Ferrari, Philips, Juventus Football Club, the Economist and Christian Louboutin. Exor’s CEO is John Elkann (Chairman of Ferrari); its Chairman is Nitin Nohria (Executive Chairman of Thrive Capital and former Dean of Harvard Business School). Lingotto’s Chairman is George Osborne, former UK chancellor.

Established in 2023, KP Rx is a 100% founder-owned investment firm specialising in private and early-stage public healthcare investments in Australia and New Zealand. Founded by Hashan De Silva and backed by Karst Peak Capital, the firm targets high-potential biotech, medical devices, diagnostics, and health tech companies at a pivotal inflection point of value creation. Our Focus Creating a portfolio of Australia’s most promising healthcare companies. Our focus is on companies at or after Series A, specifically biotech companies at Phase 2 or medical device companies at or after regulatory clearance. Small-molecule Drugs Biological Products Cell & Gene Therapies Medical Devices Diagnostic Technologies AI for Healthcare Healthcare Software / SaaS Data and Analytics

We have invested in more than 90 companies since 2016, including Pinterest, Compass, Hippo, Ro, Carta, Dutchie, Anduril, Varda Space Industries, Ghost, Front, Esusu, OKCredit, and Unqork. Additionally, through our subsidiary fund, New Slate Ventures, we have financed films, documentaries, and limited series that have been acquired by Apple, Netflix, and Disney. Based in New York City, we invest globally. Backstory Sinai Capital Partners was founded in 2017. We raised $100 million and built a talented team of young investors with offices in New York, Palo Alto, and Los Angeles. We made over 90 investments, realized 11 exits, and achieved a 1X return on our first fund within two years. In 2019, we raised $100 million for a subsidiary of Sinai Capital called New Slate Ventures, with the goal of supplying the many players in the streaming wars with independent content. Our films, series, and documentaries won Academy Award nominations, Golden Globes, Grammy’s, and Emmy’s, and were acquired by the likes of Apple, Disney, and Netflix for multiples of their cost. As a solo GP, I believe boutique, disciplined, early-stage funds with effective managers will generate the best returns for investors in this forthcoming innovation cycle. Throughout my career I’ve nurtured relationships across Silicon Valley, Wall Street, Washington DC, and Hollywood, and aim to leverage this access on behalf of the founders I support. Where to Now? We’re currently in the midst of the greatest acceleration of technological progress since 2010 and the advent of mobile/social computing. New frameworks for problem solving are emerging daily aided by artificial intelligence, CRISPR technologies, climate manipulation, and several other radical new fields previously dismissed as science fiction. When we started Sinai, the prevailing wisdom in Silicon Valley was that “hardware was hard” and that software investments provided much better risk-adjusted opportunities. That assumption is becoming less credible in the current venture capital landscape, with space exploration, brain computer interfaces, driverless electric vehicles, autonomous warfare drones, and nuclear fusion companies all appearing to be increasingly within reach, with potentially transformational impacts on civilization. Sinai’s new focus will be on these harder technical problems, as we believe this is where the majority of the value creation for this next venture cycle will emerge. While we still welcome revenue generating SaaS businesses, its become clearer to us that the best returns come from the most non-obvious ideas in undefined markets and categories. Some of our latest investments include Anduril, Varda, Galvanick, Rangeview, Factory.AI, Science.IO, and several others. We seek to invest in 5-10 companies each year, with average check sizes ranging between $1-5M depending on stage. We’re happy to lead seed rounds where we have high conviction, but prefer to collaborate with our friends at top funds across the globe. We are geographically agnostic, but are most active in New York, San Francisco, Miami, London, and the South Bay of Los Angeles.